Simcere Pharma is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market.
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 4, 2021 | Series B | ¥600M | 4 | CITIC Medical Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CITIC Medical Fund | Yes | Series B |
Tianhui Chuangtou | — | Series B |
Hongcheng Capital | — | Series B |
Nanjing Innovation Capital Group | — | Series B |